TY - JOUR
T1 - Chromogranin A and B and secretogranin II in prostatic adenocarcinomas
T2 - Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy
AU - Pruneri, Giancarlo
AU - Galli, Stefano
AU - Rossi, Roberta S.
AU - Roncalli, Massimo
AU - Coggi, Guido
AU - Ferrari, Angelo
AU - Simonato, Alchiede
AU - Siccardi, Antonio G.
AU - Carboni, Nadia
AU - Buffa, Roberto
PY - 1998/2/1
Y1 - 1998/2/1
N2 - BACKGROUND. Neuroendocrine (NE) expression in prostatic adenocarcinomas (PACs) has been related to an adverse clinical course, but the reported data are not unequivocal. METHODS. We immunostained a series of 64 PACs with three monoclonal antibodies raised against chromogranin A (CgA), chromogranin B (CgB), and secretogranin II (SgII). The patients were followed up for 18-88 months (mean 43 months, standard deviation ± 20 months); 58 of them received preoperative androgen deprivation therapy for 3-6 months. RESULTS. Of the 64 PACs under study, 39 (≃61%) were immunoreactive to CgA, 51 (≃80%) to CgB, and 38 (≃59%) to SgII. We found a strict correlation between pronounced neuroendocrine differentiation and the most poorly differentiated tumors (P = 0.01 for CgA, P = 0.03 for CgB, and P = 0.05 for SgII), and relationship (approaching statistical significance only for CgB, P = 0.07) between Cgs/Sg expression and advanced (C and D) clinical stage. However, we failed to detect any correlation between chromogranin expression and clinical outcome. CONCLUSIONS. These results suggest that NE differentiation is a frequent event in PACs, especially in the most poorly differentiated. Nevertheless, as Cgs/Sg expression is not clearly related to advanced clinical stage and poor prognosis, our findings suggest that clinical staging and grading, rather than NE differentiation, remain the most powerful prognostic indicators in PACs.
AB - BACKGROUND. Neuroendocrine (NE) expression in prostatic adenocarcinomas (PACs) has been related to an adverse clinical course, but the reported data are not unequivocal. METHODS. We immunostained a series of 64 PACs with three monoclonal antibodies raised against chromogranin A (CgA), chromogranin B (CgB), and secretogranin II (SgII). The patients were followed up for 18-88 months (mean 43 months, standard deviation ± 20 months); 58 of them received preoperative androgen deprivation therapy for 3-6 months. RESULTS. Of the 64 PACs under study, 39 (≃61%) were immunoreactive to CgA, 51 (≃80%) to CgB, and 38 (≃59%) to SgII. We found a strict correlation between pronounced neuroendocrine differentiation and the most poorly differentiated tumors (P = 0.01 for CgA, P = 0.03 for CgB, and P = 0.05 for SgII), and relationship (approaching statistical significance only for CgB, P = 0.07) between Cgs/Sg expression and advanced (C and D) clinical stage. However, we failed to detect any correlation between chromogranin expression and clinical outcome. CONCLUSIONS. These results suggest that NE differentiation is a frequent event in PACs, especially in the most poorly differentiated. Nevertheless, as Cgs/Sg expression is not clearly related to advanced clinical stage and poor prognosis, our findings suggest that clinical staging and grading, rather than NE differentiation, remain the most powerful prognostic indicators in PACs.
KW - Chromogranin A
KW - Chromogranin B
KW - Prognosis
KW - Prostatic adenocarcinomas
KW - Secretogranin II
UR - http://www.scopus.com/inward/record.url?scp=0031889712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031889712&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0045(19980201)34:2<113::AID-PROS5>3.0.CO;2-L
DO - 10.1002/(SICI)1097-0045(19980201)34:2<113::AID-PROS5>3.0.CO;2-L
M3 - Article
C2 - 9465942
AN - SCOPUS:0031889712
VL - 34
SP - 113
EP - 120
JO - Prostate
JF - Prostate
SN - 0270-4137
IS - 2
ER -